Foto del docente

Alessandra Lugaresi

Associate Professor

Department of Biomedical and Neuromotor Sciences

Academic discipline: MED/26 Neurology

Curriculum vitae

PERSONAL DATA

Born in Bologna, Italy, August 1st, 1960.

EDUCATIONAL AND PROFESSIONAL TRAINING, ACADEMIC ACHIEVEMENTS

MD, Univ Bologna, magna cum laude, July 1985

Specialist in Neurology, magna cum laude, 1989.

Ordine dei Medici di Chieti: n. 3496, since 27-oct- 1992

PhD in Neuroscience, Univ. Ancona, July 1993.

Assistant Professor in Neurology, Univ. “G. d’Annunzio”, Chieti, from April 1st , 1992 to March 31st, 2000.

Associate Professor in Neurology, Univ. “G. d’Annunzio”, Chieti, from April 1st, 2000 to March 31st, 2016.

Director MS Center in Chieti from April1st 1996 to March 31st, 2016.

Director UOSI Riabilitazione Sclerosi Multipla, April 1st, 2016 to present.

FELLOWSHIPS AND AWARDS, GRANTS

Award Associazione per le Ricerche Neurologiche (ARIN) for paper. #5 in 1987.

International fellowship from Italian Ministry of education, 1989.

“Post-Doctoral Fellow” Columbia University of New York 9/1989 - 12/1991.

Telethon Italy grant (1992-1994).

MEMBERSHIPS

Società Italiana di Neurologia (SIN)

International Society of Neuroimmunology (ISNI)

European Neurological Society (ENS)

FOREIGN LANGUAGES

Speaks fluently English and French.

TEACHING

Medicine: Neuroimmunological and paraneoplastic diseases (2014-15)

Dental School: Neurology (2004-2016)

Nursing: Neurology (2001-present)

Orthopaedics Technicians: Neurology (2016-present)

Residencies in Internal Medicine and Specialistic branches: Neurology and emergencies in neurologyMaster in Emergency: Neurological acute diseases

Master in pain Medicine: pain in neurological disorders (Multiple Sclerosis, Parkinson’s disease, …)

SCIENTIFIC ACTIVITY

Institute of Biochemistry (1980-1983).

Neurological Institute, Univ. Bologna (1984-1988).

Neuromuscular research Lab. - Columbia University - New York (14/3/1987-30/4/1987).

Institute o f Neurology and Behavioral Sciences – Univ. Chieti (1988-1989; 1991-1996)

Neuroimmunology Lab. - Columbia University (1/9/1989-31/12/1991).

Neurological institute, Dept. Oncology & Neuroscience – Univ. Chieti (1997-2010)

MS Center, Dept Neuroscience & Imaging (2010-to March 31st, 2016).

Department of Biomedical and Neuromotor Sciences (DIBINEM) of the University “Alma Mater Studiorum” of Bologna, April 1st to present.

Co-author of 194 full papers (181 on Medline, 22 1st author, 7 senior author) and > 350 abstracts (> 200 from International Meetings and published on international journals). H-index =30

Experienced in randomized, blinded clinical trials conducted according to GCP.
RECENT SELECTED REFERENCES

  • 1.Lugaresi A, De Robertis F, Clerico M, Brescia Morra V, Centonze D, Borghesan S, Maniscalco GT, On Behalf Of The River Study Group. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study. [http://www.ncbi.nlm.nih.gov/pubmed/26909646] Expert Opin Drug Deliv. 2016 Feb 24:1-5. [Epub ahead of print]. PMID: 26909646

    IF (2014) = 4,84

  • 2.Moccia M, Palladino R, Russo C, Massarelli M, Nardone A, Triassi M, Lugaresi A, Brescia Morra V. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. [http://www.ncbi.nlm.nih.gov/pubmed/26371561] Expert Opin Drug Deliv. 2015 Dec;12(12):1829-35. doi: 10.1517/17425247.2015.1078789. Epub 2015 Sep 15. PMID: 26371561

IF=4.84 (2014) Cit = 0

3. Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. [http://www.ncbi.nlm.nih.gov/pubmed/26259673] J Neuroinflammation. 2015 Aug 12;12:146. doi: 10.1186/s12974-015-0365-x. PMID: 26259673

IF=5.41 (2014) Cit. = 0

4. Lugaresi A. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis. Expert Opin Drug Metab Toxicol. 2014 Dec 16:1-12. [Epub ahead of print], PMID: 25510833

IF =3,53 (2014) Cit. = 0

5. Lugaresi A, Rottoli MR [http://www.ncbi.nlm.nih.gov/pubmed?term=Rottoli%20MR%5BAuthor%5D&cauthor=true&cauthor_uid=25109614], Patti F [http://www.ncbi.nlm.nih.gov/pubmed?term=Patti%20F%5BAuthor%5D&cauthor=true&cauthor_uid=25109614] . Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. [http://www.ncbi.nlm.nih.gov/pubmed/25109614] 2014 Sep;14(9):1029-42. doi: 10.1586/14737175.2014.945523. Epub 2014 Aug 11.

IF=2,78 (2014) Cit. = 4

6. Giordano A, Lugaresi A, Confalonieri P, Granella F, Radice D, Trojano M, Martinelli V, Solari A, on behalf of the SIMS-Practice group. Implementation of the “Sapere Migliora” information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controller trial. Multiple Sclerosis Journal 2014 Jan 13, doi:10.1177/1352458513519180

IF=4,47 Cit. = 2

7. Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain. 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18.

IF= 10.23 Cit. = 15

8. Lugaresi A, di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat. 2013;9:893-914. doi: 10.2147/NDT.S45144. Epub 2013 Jun 24.

IF= 2,00 Cit. 6

9. Lugaresi A. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence. [http://www.ncbi.nlm.nih.gov/pubmed/23252744] Expert Opin Drug Deliv. 2013 Feb;10(2):273-83. doi: 10.1517/17425247.2013.746311. Epub 2012 Dec 20.

IF= 4,12 Cit. = 7

10. Lugaresi A, Florio C, Brescia-Morra V, Cottone S, Bellantonio P, Clerico M, Centonze D, Uccelli A, di Ioia M, De Luca G, Marcellusi A, Paolillo A, The Bridge Study Group. Patient adherence to and tolerability of self administered interferon beta-1a using an electronic device: a multicentre, open-label, phase IV study. BMC Neurol. 2012 Mar 5;12(1):7. [Epub ahead of print]

IF = 2,56 Cit. = 15

11. Lugaresi A, Ziemissen T, Oreja-Guevara C, Thomas D, Verdun E. Improving patient–physician dialogue: commentary on the results of the MS Choices survey. Patient Preference and Adherence 2012;6:143-52

IF = 1,33 Cit. = 4

12. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opinion on Drug Delivery, 2009, 6:995-1002.

IF = 3,35 Cit.= 33

13. Lugaresi A, Durastanti V, C. Gasperini, M. Lai, C. Pozzilli, G. Orefice S. Sotgiu, E. Pucci, B. Ardito, E. Millefiorini and the CoSa Study Group.Safety and tolerability in Relapsing-Remitting multiple sclerosis patients treated with high dose subcutaneous interferon-beta by Rebiject Autoinjection over a 1-year period: The CoSa Study. Clin Neuropharmacol. 2008, 31:167-172.

I.F. = 2,55 Cit. = 15

I authorize the use of my personal data in accordance with Decree 196 of June 30, 2003

Latest news

At the moment no news are available.